Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,083Revenue $M13.6Net Margin (%)-295.8Altman Z-Score3.9
Enterprise Value $M1,045EPS $-0.7Operating Margin %-311.1Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.0Pre-tax Margin (%)-295.8Higher ROA y-yN
Price/Book17.010-y EBITDA Growth Rate %-6.8Quick Ratio1.3Cash flow > EarningsY
Price/Sales62.95-y EBITDA Growth Rate %4.1Current Ratio1.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-42.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-81.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M72.5ROIC % (ttm)-981.9Gross Margin Increase y-yN

Gurus Latest Trades with BCRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BCRXGeorge Soros 2014-06-30 Sold Out -0.01%$7.37 - $12.52
($9.68)
$ 15.1056%Sold Out0
BCRXGeorge Soros 2014-03-31 Buy 0.01%$7.6 - $12.83
($10.56)
$ 15.1043%New holding59,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BCRX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


BCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STAAB THOMAS R IISenior Vice President and CFO 2015-06-22Sell3,750$16-5.63 view
Barnes Alane PVP, General Counsel & Corp Sec 2015-06-19Sell3,000$150.67 view
Sheridan William PSenior VP - CMO 2015-06-19Sell70,389$15.050.33 view
STAAB THOMAS R IISenior Vice President and CFO 2015-06-19Sell16,375$14.365.15 view
Stonehouse Jon PPresident & CEO 2015-06-19Sell20,000$15.020.53 view
STAAB THOMAS R IISenior Vice President and CFO 2015-06-05Sell6,000$12.7518.43 view
STAAB THOMAS R IISenior Vice President and CFO 2015-05-18Sell3,000$1137.27 view
Babu Yarlagadda SSenior VP - Drug Discovery 2015-03-19Sell12,105$10.1648.62 view
Babu Yarlagadda SSenior VP - Drug Discovery 2015-03-05Sell37,400$10.5942.59 view
Babu Yarlagadda SSenior VP - Drug Discovery 2015-03-04Sell10,495$10.543.81 view

Quarterly/Annual Reports about BCRX:

    News about BCRX:

    Articles On GuruFocus.com
    comment on BCRX Mar 02 2013 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 

    More From Other Websites
    BioCryst Pharm upgraded by BofA/Merrill Jun 30 2015
    Watch out! These 2 stocks are in jeopardy: Pro Jun 25 2015
    2 Stocks to fall Jun 23 2015
    Tekmira Tumbles On Ominous Signs For Ebola Drug Jun 19 2015
    Strength Seen in BioCryst (BCRX): Stock Rises 9.9% - Tale of the Tape Jun 19 2015
    BioCryst to Present at the JMP Securities Life Sciences Conference Jun 18 2015
    BioCryst to Present at the JMP Securities Life Sciences Conference Jun 18 2015
    Durham's BioCryst cuts $45 million deal with Australian firm Jun 17 2015
    BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jun 17 2015
    BioCryst Licenses Worldwide Rights to Commercialize RAPIVAB(R) Influenza Treatment to CSL Limited Jun 17 2015
    BioCryst Licenses Worldwide Rights to Commercialize RAPIVAB(R) Influenza Treatment to CSL Limited Jun 17 2015
    RA Capital Management returns an estimated 10.09% for May Jun 03 2015
    BioCryst to Present at the Jefferies 2015 Healthcare Conference May 26 2015
    BioCryst to Present at the Jefferies 2015 Healthcare Conference May 26 2015
    BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 22 2015
    BIOCRYST PHARMACEUTICALS INC Financials May 15 2015
    BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 13 2015
    BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX7353 for the Treatment of Hereditary... May 13 2015
    BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX7353 for the Treatment of Hereditary... May 13 2015
    Oppenheimer Reviews BioCryst Earnings May 11 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK